Natural Alternatives International Inc의 펀더멘털은 비교적 안정적 상태이며, ESG 공시는 업계를 선도하는 수준입니다.성장 잠재력은 높습니다.기업의 밸류에이션은 적정하게 평가된 것으로 간주되며, 제약 산업에서 159개 중 115위 랭킹.기관 보유 비율은 매우 높은.중기적으로 주가는 상승 추세일 것으로 예상됩니다.지난 한 달간 주식 시장에서 매우 부진한 성과를 거두었지만, 기업의 펀더멘털과 기술적 지표는 탄탄합니다.주가는 지지선과 저항선 사이에서 횡보하고 있으며, 범위 매매 기반의 스윙 트레이딩에 적합한 상황입니다.
Natural Alternatives International Inc 점수
관련 정보
산업 순위
115 / 159
전체 순위
359 / 4521
산업
제약
저항선 & 지지선
기업이 아직 관련 데이터를 공개하지 않았습니다.
레이더 차트
현재 가격
과거
미디어 보도
최근 24 시간
보도 수준
매우 낮은
매우 높은
중립
Natural Alternatives International Inc 주요 내용
강점위험 요소
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.